The deal, which has been in the works for months, hands the German pharmaceutical company two approved drugs for rare tumors.

Interim results from a study in China suggest ivonescimab may reduce the risk of death versus Keytruda, but the difference ...

Spruce Biosciences is cutting over half of its employees as it looks to secure accelerated approval of a Sanfilippo syndrome ...